4-羟基苯甲酰乙酸 | 62024-30-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 4-羟基苯甲酰乙酸
• 英文名称: 4-hydroxybenzoylacetic acid
• 英文别名: 3-(4-Hydroxyphenyl)-3-oxopropanoic acid
• CAS: 62024-30-0
• 化学式: C₉H₈O₄
• mdl: MFCD20653742
• 分子量: 180.16
• InChiKey: HRXAQVGNCWFWTL-UHFFFAOYSA-N

物化性质

• 熔点：
  150 °C(Solv: water (7732-18-5))
• 沸点：
  464.0±25.0 °C(Predicted)
• 密度：
  1.380±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-羟基苯甲酰乙酸 在 硫酸 作用下， 以60%的产率得到对羟基苯乙酮
  参考文献：
  名称：

  Herbert, Richard B.; Jackson, Frederick B.; Nicolson, Ian T., Journal of the Chemical Society. Perkin transactions I, 1984, # 4, p. 825 - 831

  摘要：

  DOI：
• 作为产物：
  描述：

  4-benzyloxybenzoylacetic acid 在 palladium on activated charcoal 氢气 作用下， 以 乙醇 为溶剂， 以93%的产率得到4-羟基苯甲酰乙酸
  参考文献：
  名称：

  Herbert, Richard B.; Jackson, Frederick B.; Nicolson, Ian T., Journal of the Chemical Society. Perkin transactions I, 1984, # 4, p. 825 - 831

  摘要：

  DOI：

文献信息

• [EN] NOVEL COELENTERAZINE SUBSTRATES AND METHODS OF USE<br/>[FR] NOUVEAUX SUBSTRATS DE COELENTÉRAZINE ET PROCÉDÉS D'UTILISATION
  申请人：PROMEGA CORP

  公开号：WO2012061529A1

  公开（公告）日：2012-05-10

  An isolated polynucleotide encoding a modified luciferase polypeptide and novel coelenterazine- based substrates. The OgLuc variant polypeptide has at least 60% amino acid sequence identity to SEQ ID NO: 1 and at least one amino acid substitution at a position corresponding to an amino acid in SEQ ID NO: 1. The OgLuc variant polypeptide has at least one of enhanced luminescence, enhanced signal stability, and enhanced protein stability relative to the corresponding polypeptide of the wild-type Oplophorus luciferase.

  一个编码修改后的荧光酶多肽和新型荧光素基底的孤立的多聚核苷酸。OgLuc变体多肽至少具有与SEQ ID NO: 1的氨基酸序列相同性的60％，并且至少在一个位置上具有与SEQ ID NO: 1中的氨基酸对应的氨基酸替换。相对于野生型Oplophorus荧光酶的相应多肽，OgLuc变体多肽至少具有增强的荧光、增强的信号稳定性和增强的蛋白稳定性中的至少一种。
• AMIDE DERIVATIVES AND DRUG COMPOSITIONS
  申请人：Nippon Shinyaku Co., Ltd.

  公开号：EP1156045A1

  公开（公告）日：2001-11-21

  The present invention is composed of an amide derivative represented by the following formula [1] or pharmaceutically acceptable salt thereof:    wherein R1 and R2 may be the same or different and each is hydrogen, alkyl which may be substituted, acyl, aryl which may be substituted, or an aromatic heterocyclic group which may be substituted; R3, R4, R5, and R6 may be the same or different and each is hydrogen, halogen, hydroxy, amino which may be substituted, alkyl which may be substituted, alkoxy, or nitro and the like; and R7 represents cyclic amino which may be substituted or azabicycloalkylamino which may be substituted, and a pharmaceutical composition which comprises it as an active ingredient. The compound of the invention is useful as an inhibitor of TGF-β production or an antagonist of TGF-β.

  本发明由下式[1]代表的酰胺衍生物或其药学上可接受的盐组成： 其中R1和R2可以相同或不同，各自为氢、可被取代的烷基、酰基、可被取代的芳基或可被取代的芳杂环基团；R3、R4、R5和R6可以相同或不同，各自为氢、卤素、羟基、可被取代的氨基、可被取代的烷基、烷氧基或硝基等；R7代表可被取代的环氨基或可被取代的氮杂环烷基氨基，以及将其作为活性成分的药物组合物。 本发明的化合物可用作 TGF-β 生成的抑制剂或 TGF-β 的拮抗剂。
• MEDICINAL COMPOSITION
  申请人：Nippon Shinyaku Co., Ltd.

  公开号：EP1243268A1

  公开（公告）日：2002-09-25

  The present invention is composed of a pharmaceutical composition for the therapy of nephritis which comprises an amide derivative represented by the following formula [1] or pharmaceutically acceptable salt thereof, as an active ingredient:    wherein R1 and R2 may be the same or different and each is hydrogen, alkyl which may be substituted, acyl, aryl which may be substituted, or an aromatic heterocyclic group which may be substituted; R3, R4, R5 and R6 may be the same or different and each is hydrogen, halogen, hydroxy, amino which may be substituted, alkyl which may be substituted, alkoxy or nitro and the like; and R7 represents cyclic amino which may be substituted or azabicycloalkylamino which may be substituted. The pharmaceutical composition of the invention is useful for the therapy of nephritis.

  本发明由一种治疗肾炎的药物组合物组成，该药物组合物包括下式[1]代表的酰胺衍生物或其药学上可接受的盐作为活性成分： 其中 R1 和 R2 可以相同或不同，各自为氢、可被取代的烷基、酰基、可被取代的芳基或可被取代的芳香杂环基团；R3、R4、R5 和 R6 可以相同或不同，各自为氢、卤素、羟基、可被取代的氨基、可被取代的烷基、烷氧基或硝基等；R7 代表可被取代的环氨基或可被取代的氮杂环烷基氨基。 本发明的药物组合物可用于治疗肾炎。
• PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR
  申请人：Institute of Medicinal Molecular Design, Inc.

  公开号：EP1666469A1

  公开（公告）日：2006-06-07

  A medicament having inhibitory activity against plasminogen activator inhibitor-1, which comprises as an active ingredient a compound represented by the following general formula (I) or a salt thereof: wherein R1 and R2 represents an aromatic group which may be substituted, W represents a group selected from the following connecting group W-1: (wherein a bond at the left end binds to the carbon atom and a bond at the right end binds to the nitrogen atom, X represents sulfur atom or NH, Y represents oxygen atom or sulfur atom, R3 represents a hydrocarbon group, hydroxy group, or carboxy group), Z represents a single bond or a connecting group wherein a number of atoms in a main chain is 1 to 3.

  一种对纤溶酶原激活物抑制剂-1 具有抑制活性的药物，其活性成分包括下式（I）所代表的化合物或其盐： 其中 R1 和 R2 代表可被取代的芳香基团、 W 代表选自下列连接基 W-1 的基团： (其中左端的键与碳原子结合，右端的键与氮原子结合、 X 代表硫原子或 NH Y 代表氧原子或硫原子、 R3 代表烃基、羟基或羧基）、 Z 代表单键或连接基团，其中主链中的原子数为 1 至 3。
• Acyclovir diester derivatives
  申请人：Drug Innovation & Design, Inc.

  公开号：US20010012893A1

  公开（公告）日：2001-08-09

  Disclosed are novel prodrugs represented by the following structural formula: 1 Z is oxygen or sulfur; Y is, together with a hydroxy group, acyclovir or an analog of acyclovir; A is a substituted benzyl group with one or more protected hydroxy or protected amine groups in the ortho or para positions, relative to the phosphate ester, which can be converted in vivo to a hydroxy or amino group. Also disclosed is a method of treating a viral infection in an individual or animal. The method comprises administering to the individual or animal a therapeutically effective amount of a prodrug represented by structural formula shown above.

  所公开的是由以下结构式表示的新型原药： 1 Z是氧或硫；Y与羟基一起是阿昔洛韦或阿昔洛韦类似物；A是取代的苄基，相对于磷酸酯，在正位或对位上有一个或多个受保护的羟基或受保护的胺基，可在体内转化为羟基或氨基。还公开了一种治疗个体或动物病毒感染的方法。该方法包括向个体或动物施用治疗有效量的由上述结构式代表的原药。